To examine whether regulators of ECM internalisation may impact on chemoresistance in breast cancer patients, we looked at the correlation between MAP3K1, MAPK11, PPP2R1A, and α2 integrin expression and chemotherapy response using transcriptomic data of 3,104 breast cancer patients [57]. The gene discussed is PPP2R1A; the disease is breast carcinoma.